who discovered glp-1 agonists Evolution of GLP‐1 Receptor for Diabetes Treatment GLP-1s: The world's first longevity

doi: 10.1172/jci.insight.133429 171 ZhangFTongYSuNLiYTangLHuangLet al

Similar effects were seen with liraglutide, the active ingredient in the weight loss drug Saxenda, and the diabetes drug Victoza

Our observations about the efficacy of GLP-1 RAs in enhancing survival and reducing cardiovascular events are concordance with evidence from several cardiovascular outcome trials (CVOTs) conducted in general population with T2DM, as well as a recent cohort study focused on solid organ transplant recipients [16,17,18,19, 23]

Gastrointestinal adverse events Compared with placebo, nausea was more frequent with all tirzepatide doses, especially 15 mg (OR 5.60 [95% CI 3.12, 10.06], I 2 0%) (Table 2)

Recent findings from the SUSTAIN-7 study demonstrated semaglutide's superiority over dulaglutide in enhancing glycaemic management and facilitating significant weight reduction, while preserving similar safety profiles (Pratley et al